Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Global Blood, FDA agree on fast-filing plan for new sickle cell disease drug

  • Adam Feuerstein

By Adam Feuerstein Dec. 3, 2018

Reprints
ASH19 Gene Therapy Sickle Cell
Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia via AP

Updated from 8 am EDT with new clinical trial data.

SAN DIEGO — Global Blood Therapeutics (GBT) said Monday that it had reached an agreement with the Food and Drug Administration for an accelerated approval submission of its experimental drug to treat sickle cell disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Stanford scientist who broke genome sequencing record on what…
Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients
Will there be any emergency doctors to see you…
Will there be any emergency doctors to see you in the future?
The fungal crisis is here and desperately needs addressing
The fungal crisis is here and desperately needs addressing
89bio treatment reduces liver scarring in patients with NASH,…
89bio treatment reduces liver scarring in patients with NASH, meeting study goals
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data
8 burning questions Bernie Sanders and other senators should…
8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

Recommended Stories